When Patents Kill Innovation – The Daily Dish | By Andrew Sullivan
Interesting set of thoughts. Maybe going opensource and relying on the stickiness of IP as property of local intellectual networks might be a better approach to innovation in Ireland – especially if coupled to a realistic innovation and commercialisation agenda (and not the intuitively-appealing but empirically unfounded ideas presented by certain politicians, as discussed here in a previous post).
Blog post reproduced in full:
Michelle Geis points to a new report in Genetics in Medicine suggesting that “exclusive licensing of gene patents does more to block competition and decrease patients’ access to testing than it does to spur innovation.” The Economist has more:
“For example, where gene-testing monopolies do not accept the miserly reimbursements offered by Medicaid—the American government health scheme for the poor—the indigent suffer. Furthermore, the lack of a rival provider of tests to get a second opinion makes it impossible to ensure that results are accurate.
Even more striking is the claim made by the Duke researchers that patent exclusivity is not necessary to spur innovation in genetic testing. Dr Cook-Deegan argues that testing, unlike pricey drug development, has low barriers to entry and is relatively cheap, so a monopoly is not required to lure investors. As evidence, he points to the case of cystic fibrosis: unlike breast cancer, no monopoly patent blocks access to the relevant gene, and dozens of rival testing companies flourish.”